BQ123
Phase 1Small molecule
BQ123 is one of 100 small molecule programs targeting Vasculitis. It is currently in Phase 1.
3
Indications
3
Total Trials
0
Active Trials
99
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Byetta
AstraZenecaPreclinical
Jardiance
Boehringer IngelheimPreclinical
NOVOLIN R
Novo NordiskPreclinical
Glargine
Eli LillyPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BQ123. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- VVanderbilt University